NCT02537223View on ClinicalTrials.gov

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 14, 2018

Study Completion Date

February 20, 2020

Conditions

Squamous Cell Carcinoma of Head and NeckLocoregionally Advanced

Interventions

DRUG

BYL719

DRUG

Cisplatin

RADIATION

Intensity modulated radiation therapy (IMRT)

Trial Locations (1)

M3G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University Health Network, Toronto

OTHER